André-Jean REMY (1,2) (1) Hepatitis Mobile Team, Service of Gastroentrology, (2)Consultation Unit and Ambulatory Care, Hepatitis Reference Center, Perpignan.

Slides:



Advertisements
Similar presentations
Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Advertisements

Integration of Viral Hepatitis Prevention with STD Prevention: What Health Professionals Should Know Presenter: Jay Todd, Training and Public Education.
Coordinator, Harm Minimisation & Hepatitis Programs South Eastern Sydney Local Health District Hepatitis and the holy grail Gary Gahan.
Steven Saunders, MS, Director, HIV Prevention DHSTS, NJDOH.
Systematic TB Screening: Philippine Experience The 9th Technical Advisory Group and National TB Program Mangers meeting for TB control in the Western Pacific.
“Humanitarian Action” The Saint-Petersburg Charitable Foundation for Medical and Social Programs HAF.
Hepatitis C In Alaska’s Department of Corrections
HIV Prevention, treatment and care among people who inject drugs Fabienne Hariga, MD, MPH Senior HIV Adviser, UNODC Vienna.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
HIV AIDS Section Fabienne Hariga Senior Adviser UNODC HIV AIDS section, Vienna Comprehensive package of interventions for HIV in prison settings AIDS 2012.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
SANTANA P. ABRAVANEL L., AUBERT JP.PICARD H. GELLY J. FRARIER M. 1 PREVAC A An evaluation of preventive Hepatitis A vaccination in risk groups WONCA EUROPE.
Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust.
Larry Cuellar Adult Viral Hepatitis Prevention Coordinator Texas Department of State Health Services 2010 STREET OUTREACH WORKERS CONFERENCE June 21, 2010.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1.
Results from the Spanish experience: A comprehensive approach to HIV and HCV in prisons MERCEDES GALLIZO LLAMAS Secretary-General of Spanish Prison Administration.
The implementation of the National Tuberculosis Control Program at a regional level: Voronezh TB Service JULY 13, 2015 Dr. Kornienko, Sergey.
Sara Stevenson Hepatitis B Nurse Specialist St James’s Hospital, Leeds.
HEPATITIS MOBILE TEAM News Tools of screening viral hepatitis in real life: the french model of care André-Jean REMY (1,2), Hugues WENGER (1), Hakim BOUCKHIRA.
1 Counseling and HIV Testing HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Pennsylvania: The State of HCV 2015
Module 4: Testing and monitoring. Module 5: Testing and monitoring Module goal To introduce participants to best practice regarding the different tests,
Suppressing the Hepatitis C virus, Barriers to Care American Public Health Association APHA 143 rd Annual Meeting&Expo October 31-November 4,2015, Chicago,
Brussels, 20th November 2014 Françoise WEIL, Managing Director Plate-forme de Concertation pour la Santé Mentale en Région Bruxelles-Capitale
A Universal Testing Programme for Blood Borne Viruses in an Urban Emergency Department – a call for widespread ED testing in Ireland S O’Connell 1, D Lillis.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
Early TB case detection in pre-trial detention centers (SIZOs) and prison colonies in Ukraine 46 th Union World Conference on Lung Health Cape Town, South.
HEALTH CARE, DRUG USE AND EPIDEMIOLOGY OF INFECTIOUS DISEASES IN PRISONS SYSTEM OF LITHUANIA BIRUTE SEMENAITE, VLADAS RIMGAUDAS KASPERUNAS, MEDICAL DIVISION.
Bulgarian National Hepatitis Plan and Compassionate Use Regulations Dr. Stanimir Hasardzhiev Executive Director, ELPA Chairperson, Hepasist REPUBLIC OF.
EG HIV/AIDS & AI Internal Strategy and Action Plan Country priorities according to a survey in January-February 2014.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Jana Feldmane Ministry of Health of Latvia Public Health Department Health care overview in prisons.
#AIDS2016 HOW TO LAUNCH PROGRAMMES FOR PEOPLE WHO USE SUBSTANCES AND ARE AFFECTED BY HIV ACROSS MORE GENERALIZED HIV EPIDEMIC SETTINGS.
LOW HCV PREVALENCE AMONG HIV+ INDIVIDUALS IN SUB-SAHARAN AFRICA
Deadly trio: mental health – HIV - drugs
Durban, July 20th 2016 Ruggero Giuliani MSF - Mozambique
SITUATION WITH TUBERCULOSIS AND OTHER INFECTIOUS DISEASES IN LATVIAN PRISONS PROGNOSIS AND CHALLENGES Riga, 29 – 30 May 2008.
MEDICS CATALONIA PROJECT
Effective HIV & SRH Responses Among Sex Workers and other Key Populations Module 1: National Data.
Monitoring and Evaluation Frameworks
General Situation (Overview)
(2)Consultation Unit and Ambulatory Care,
Government of Swaziland
BIRUTE SEMENAITE, MEDICAL DIVISION OF THE PRISON DEPARTMENT
Enhanced Pharmacy Provision in Edinburgh:
Current harm reduction program at outreach
Integrating Hepatitis C Treatment in Primary Care
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Rowe, KA1, Tesoriero, JM1, Davis, SJ1, Heavner, KK1, Rothman, J2,
Reitox National Focal Point National Bureau for Drug Prevention
Hepatitis B and C management pathways in prison:
Core Competency 4: HCV Treatment
Preventing and Treating STIs and HIV / AIDS
Testing and linking different key population groups in Ukraine
Treating Hep C with Novel Agents
INTEGRATE satellite symposium AIDS 2018, Amsterdam, the Netherlands
Mark Lobato, MD Division of TB Elimination
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
HCV Screening.
Edward Mbizo Sibanda, (MSc) Right to Care
HEPCARE EUROPE Lessons learned on HCV testing and treatment through outreach to the community and linkage-to-care Dr. Jack Lambert Dublin │ London │
Blood borne viral hepatitis action in Wales
Progress in Facilitating National HCV Prevention
Primary Care Treatment of Hepatitis C
Hepatitis C Virus Diagnosis and the Holy Grail
Professor Jack Lambert
Lesson 3: Treatment as Prevention
Hepatitis C case-finding – An opportunity for community pharmacy
Presentation transcript:

André-Jean REMY (1,2) (1) Hepatitis Mobile Team, Service of Gastroentrology, (2)Consultation Unit and Ambulatory Care, Hepatitis Reference Center, Perpignan Hospital, France INCIDENCE OF THE HEPATITIS C IN PRISON IN FRANCE RESULTS OF A STUDY BY POCT HEPATITIS MOBILE TEAM 1 1

800 km 200 km Barcelona 2

HCV in France (1)  Global incidence 2700/4400 new cases per year  HCV patients  unaware patients  waiting for treatment  cured patients 3

HCV in France (2)  Number of treated patients  2012   2013  6000  2014   2015 

French guidelines February / Treat all patients with liver fibrosis F2 F3 F4 and.. 2/ Treat all drugs users and inmates even if no liver fibrosis  100% of french DU / inmates have to be treated for HCV infection! 4 5

2016 HEPATITIS MOBILE TEAM  1 Hepatologist  1 Nurse coordinator  3 other nurses (2 for psycho educative intervention)  1 Secretary  2 Social workers  2 Health care workers  For a multidisciplinary approach 8 6

HEPATITIS MOBILE TEAM - 3 specific cars + 1 truck -3 Fibroscan - POCT/DBS HIV/HCV/HBV 9 7

Target population  Drugs users  Prisoners  Psychiatric patients  Homeless  Precarious people  Migrants 8

PARTNERS ORGANIZATIONS HEPATITIS MOBILE TEAM Associative sector Patients association Psychoeducative network Hepatitis network Hospital services Asyleum medical unit Jailhouse medical unit Primary care access unit Pharmacy TB unit Addictology service Gastroenterology service Medical duty home Psychiatric Hospital One Day hospital and Psychiatric Mobile Team Mao – psychiaitric diagnosis and orientation module Outside hospital Methadon centers Low threesold drug center Housing units Therapeutic Coordination Apartment Day reception and home association 10 9

PARTNERS ORGANIZATIONS HEPATITIS MOBILE TEAM Associative sector Patients association Psychoeducative network Hepatitis network Hospital services Asyleum medical unit Jailhouse medical unit Primary care access unit TB unit Addictology service Gastroenterology service Medical duty home Psychiatric Hospital One Day hospital and Psychiatric Mobile Team Mao – psychiaitric diagnosis and orientation module Outside hospital Methadon centers Low threesold drug center Housing units Therapeutic Coordination Apartment Day reception and home association people area 10

15 SERVICES « à la carte »  Early detection / Primary prevention 1. Screening / Point of Care Testing POCT (HIV HBV HCV) 2. Green thread: outside POCT/DBS (dried blood spot) and FIBROSCAN* with specific truck 3. Outreach open center 5 days/7 4. Drug users information and prevention actions 5. Staff training  Clinical management :Linkage to care and fibrosis assesment 6. Social screening and diagnosis (EPICES score) 7. Mobile liver stiffness Fibroscan* (indirect measurement of liver fibrosis) in site 8. Advanced on-site specialist consultation 9. Free access to hospital blood tests care 13 11

15 SERVICES « à la carte »  Access to treatment 10. Easy access to pre-treatment commission (“RCP”) with hepatologists, nurse, pharmacist, social worker, GP, psychiatric and/or addictologist Low cost mobile phones for patients  Follow up during and after treatment 12. Individual psychoeducative intervention sessions 13. Collective educative workshops 14. Peer to peer educational program 15. Specific one day hospitalizations 13 12

15 SERVICES « à la carte »  Hepatitis mobile team offers hotlines "all in one"  Each structure according to its needs could choose actions it wishes to include in its draft  For 1500 potential outpatients 14 13

244 HCV followed patients 14

1485 seen once 2056 DBS / 944 HCV DBS/ 414 Fibroscan HCV positive 244 (100%) FIBROSCAN + full blood tests done 202 patients in pretreatment commission(83 %) (61% of PTC cases) 146 HCV treatment decide (59%) / 56 only survey 121 started treatment(50%) 93 cured patients + 26 in treatment (49%) / only 2 stop treatment HMT linkage care 15

Introduction (1)  HCV rate is higher in the prisoners population than in the general’s one in France, between 5 and 7 % (INVS 2004, PREVACAR)  Prisoners accumulate risk factors before their confinement but the prison in itself represents a risk factor: syringes or straw share, home-made tattoos… 16

Introduction (2)  HCV incidence in prisons was not known  Screening of HCV is systematically proposed in the entrance to detention in France, recommended by the Methodological Guide of sanitary care is not still applied correctly  point of care testing (POCT) use could constitute an interesting alternative in classic serology  POCT was recommended in French HCV experts report in 2014 and in national guidelines in

Objective  use HCV POCT in prison  as a supplement to the classic serology  study the incidence of new HCV infections in prisoners 18

Methods (1)  HCV prevalence in our establishment is situated in national average around 7 %  HCV serology realized by venous way was proposed to all incomers in Perpignan detention center  average 1500 per year 19

Methods (2)  POCT was proposed to 3 types of prisoners:  1/refusal or impossibility of venous way  2/transfer of another penitentiary and previous negative serology  3/presence in detention 12-month- old superior and previous negative serology 20

Point Of Care Testing  POCT/DBS HCV / HIV / HBV  Alternative to blood test, but in case of positive test  blood test confirmation is necessary  Quick on digital puncture  Immediate results  Free, renewal of HCV status as soon as necessary 15 21

Methods (2)  In case of positivity  we did FIBROSCAN  And complementary blood tests 22

Mobile FIBROSCAN Liver stiffness = measurement of hepatic elasticity to detect liver fibrosis and liver cirrhosis diagnosis Uninvasive testing with rapid results, combined with DBS/POCT Performed by a nurse trained in the framework of a Memorandum of Cooperation (HSPT-Law Article 51) 16 23

Results (1)  333 HCV POCT was realized in 24 months  group 1 15 % (refusal)  group 2 27 % (transfer)  group 3 58 % (> 12 months detention) 24

Results (2)  2 serology were positive by POCT  2 inmates were imprisoned for more than 6 months  viral load was both positive  One patient had gone out in permission one week  One patient had never gone out of detention  Use of drugs was route of contamination in 2 cases 25

Results (3)  Calculated incidence in prison was 3/1000/year  potentially 470 new cases of HCV infection in France a year among the prison population  prisoners on May 1st, 2016 in France 26

Risk of HCV reinfection in IVDU and prisoners  Simmons and al, CID 2016: 62,  14 studies high-risk patients IVDU and prisoners  Risk rate = 22.3/1000 person years of follow up after HCV treatment 27

Discussion / conclusions  HCV POCT are useful in jailhouses because there are HCV high risk place  These route of contamination could be more than 10% of HCV new cases  So it was also necessary to give harm reduction tools for all prisoners like syringes share 28

THANK YOU FOR YOUR ATTENTION !!! 29

ANY QUESTIONS ? 30